leadf
logo-loader
viewBiocept Inc

Biocept 1Q revenue jumps by double-digits while closing with $21.5M in cash

The San Diego company that develops liquid biopsy tests clocked $1.4 million in revenue for a 41% year-over-year increase 

Biocept Inc - Biocept 1Q revenue jumps by double-digits as its closes with $21.5M in cash
The company is developing COVID-19 diagnostic test, creating another potential revenue stream

Biocept Inc (NASDAQ: BIOC) saw revenue jump by double-digits in the first three months of 2020 as it closed its first quarter with cash and cash equivalents of $21.5 million.

In a statement Wednesday, the San Diego-based company that develops liquid biopsy tests for commercial use clocked $1.4 million in revenue, nearly all of it from testing revenue. That’s a 41% year-over-year increase. 

Biocept has developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA). It offers the tests to doctors, hospitals, clinics and researchers, with a focus on lung, breast, gastric, colorectal and prostate cancers as well as melanoma.

READ: Biocept's mutation-detecting Target Selector kits get nod from EU regulators

The company also is developing a coronavirus (COVID-19) diagnostic test, creating another potential revenue stream. 

"Revenue for the first quarter was $1.4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession," said CEO Michael Nall.

"We increased revenues even with the headwinds of the COVID-19 pandemic, which we estimate led to an approximate 15-25% decline in commercial volume from current customers and also impacted opportunities for us to gain new customers with the closing of many physician offices and labs." 

Nall added: "Importantly, we believe we are well-positioned to weather the pandemic, which is impacting testing volume industrywide, and for a return to growth as shelter-in-place restrictions are lifted and physician offices and labs reopen."

He said the company expects that when it is safe for patients diagnosed with cancer to continue to seek treatment, its commercial volume will return to a more normal level.  

“We are particularly pleased with our strengthened balance sheet, having raised approximately $36.3 million in net proceeds since the beginning of December 2019,” Nall said.

"While we believe that based on historical and planned cash usage, our current funding is expected to support operations through most of 2021; however, with the uncertainty introduced by the impact of COVID-19 on revenue and collections, our cash runway may be shorter."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham 

 

Quick facts: Biocept Inc

Price: 4.36 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $58.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read